$RLAY News

Guggenheim Maintains Buy on Relay Therapeutics, Raises Price Target to $26

HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Raises Price Target to $28

Relay Therapeutics, Inc. (RLAY) Presents at ISSVA World Congress 2026: The Latest in Vascular Anomalies - Slideshow

Relay Therapeutics: Encouraging Data, Competitive Risks (Downgrade)

Relay Therapeutics, Inc. (RLAY) Discusses Initial Clinical Data for Zovegalisib in Vascular Anomalies - Slideshow

Barclays Maintains Overweight on Relay Therapeutics, Raises Price Target to $27

Citizens Maintains Market Outperform on Relay Therapeutics, Raises Price Target to $21

Relay Therapeutics: Zovegalisib Is Becoming A Platform In Disguise

Relay Therapeutics, Inc. (RLAY) Discusses Initial Clinical Data for Zovegalisib in Vascular Anomalies Transcript

This Biotech's Drug Just Wiped The Floor With Forecasts

Relay Therapeutics Announces Proposed Public Offering of Common Stock

Relay Therapeutics Launches $175M Public Stock Offering

Raymond James Maintains Strong Buy on Relay Therapeutics, Raises Price Target to $26

Relay Therapeutics shares jump after positive vascular anomalies trial results (RLAY)

Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies

Relay drug shows early promise against rare blood vessel diseases

Relya Therapeutics Announces Initial Clinical Data From The Phase 2 ReInspire Trial Of Zovegalisib In Vascular Anomalies

Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million

H.C. Wainwright is Bullish on Relay Therapeutics, Inc. (RLAY)

Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Are Cutting Their Estimates: Here's What You Need To Know